Most patients who benefited from anti-PD-1 therapy tended to have CD8+ T cell infiltration and higher PD-L1 expression in tumor tissue, and the expression of PD-L1 was significantly associated with CD8 density (31). This evidence concerns the gene CD8A and neoplasm.